Conviction
0 → 2
Current stock research snapshot · 7/31/26 26 days old
ELVElevance Health
Investment conviction●●○○○2 of 5 · current snapshot
Research target$487.78Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/31/26
Market cap$81.54BSnapshot value · 7/31/26
Research history
See all ELV changes ↗What changed
Target
$487 → $487.78
Healthspan taxonomy seed — see taxonomy_path
Elevance Health Q2 2026 earnings; medical cost ratio (MLR) trends; Medicare Advantage member growth
Thesis breaks if Medicaid exits (margin-negative ~-1.75% on ~$57B) spread, medical membership keeps shrinking (469K QoQ to 44.9M), or DCP float erosion (1.2 days QoQ) continues. (vault 2026-08)
Neutral — No significant X discussion found in the last 30 days. [X search Aug 2026]
Snapshot · 7/31/26🟢 Lean-Bull · 13F 8+/16-×0.5 · short↓0.19
Snapshot · 7/31/26Timestamped research update
Deep research update
645 words · Updated Aug 15, 2026 · 3 sources
Research in development: this latest 645-word update is published for context while it is expanded toward the 1,000-word editorial standard.
Elevance Health (formerly Anthem) is a U.S. managed-care organization and health-services platform. It operates two reportable segments — Health Benefits (Individual, Employer Group, Medicare, Medicaid, Federal Employee Program, BlueCard) and Carelon (CarelonRx pharmacy/PBM plus Carelon Services: behavioral, home, and complex care). The economic engine is not care delivery but risk-pooling at scale: it earns a thin spread between premiums collected and medical claims paid, amplified by investment income on claims float and a growing services layer.
Q2 2026 operating revenue was $49.8B, up 0.8% YoY (vs $49.4B in Q2 2025). Q2 diluted EPS was $6.71 GAAP and $7.45 adjusted. Net income was $1.463B (XBRL). Medical membership was ~44.9M as of June 30, 2026, and the company serves ~104M consumers across its full portfolio. FY2026 guidance was raised: adjusted diluted EPS to at least $27.00 (from prior), GAAP diluted EPS to at least $20.10, and operating cash flow to at least $6.0B.
The moat is regulatory-licensed risk pooling plus network scale plus claims float. A competitor cannot replicate 44.9M medical members, ~104M consumers, the Blue Cross Blue Shield license/network access, and the actuarial + claims infrastructure without a decade of state-by-state licensure, provider contracting, and reserving history. Elevance converts this into: (a) an interest-earning claims float of roughly $22B, (b) a pharmacy/services layer (Carelon) that grows faster and at higher margin than the base risk book, and (c) pricing power against providers.
- Q2 2026 benefit expense ratio (BER, the managed-care equivalent of MLR) was 89.7%, up 80 bps YoY but ahead of expectations (per the 8-K EX-99.1 release).
- Health Benefits segment operating margin compressed to 2.1% (from 3.8% YoY); operating gain fell to $0.9B from $1.6B — the government lines are the drag.
- Carelon revenue grew 6% YoY to $19.2B with a 4.9% operating margin, on scaling Carelon Services risk-based solutions and CarelonRx product revenue.
- Days in Claims Payable (DCP) was 45.4 days, up 2.9 days YoY (more float) but down 1.2 days sequentially.
- The company repurchased 0.7M shares for $234M at a weighted average $344.62 in Q2, paid a $1.72/share quarterly dividend, and retains ~$5.3B of buyback authorization.
- Management framed 2026 as a margin trough and reaffirmed a return to at least 12% adjusted EPS growth in 2027 off the 2026 baseline.
Three reinforcing, source-backed barriers. (1) Regulatory licensure + network incumbency — multi-year, state-awarded Medicaid contracts and employer ASO contracts carry high switching costs because re-procurement and member transition are costly and risky. (2) Claims float — DCP of 45.4 days means Elevance holds premium dollars ~45 days before paying claims, a structural interest-earning float. (3) Carelon vertical integration — owning the PBM and specialty pharmacy captures the margin that otherwise leaks to a third-party pharmacy partner.
- A sustained government-program BER re-acceleration (higher acuity on lagged state Medicaid rates) would compress Health Benefits margin toward zero.
- Federal/state policy shifts — work requirements affecting ~20% of the Medicaid book, MA risk-adjustment and prior-authorization scrutiny — can reset reimbursement faster than premiums can be re-priced.
- The commercial book, while higher-margin, is not immune to a labor-market slowdown that shrinks employer-group risk membership.
- Can the Carelon services layer (mid-single-digit growth, higher margin) scale fast enough to offset the structurally lower-margin government risk book?
- Does the CMS star-ratings litigation resolve favorably and restore the ~$115M bonus-payment run-rate?
- Which additional Medicaid states does management exit, and what is the EPS accretion/headwind from each?
INTACT — the float + network-scale + Carelon moat is real and source-backed, but current economics are compressed (Health Benefits margin 2.1%, Medicaid margin-negative), and the re-rating catalyst is the 2027 government-line margin recovery management is guiding to. First-pass conviction stays moderate.
Primary and supporting material
Sources
3 sources preserved from the latest qualified research update.